Progress in the diagnosis and treatment of autoimmune hepatitis

Minerva Medica

Volumn 99, Issue 6, 2008, Pages 549-568

  Czaja, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune; Diagnosis Hepatitis; Hepatitis; Therapy Liver diseases

Indexed keywords

ALENDRONIC ACID; AUTOANTIBODY; AZATHIOPRINE; BIOLOGICAL MARKER; BUDESONIDE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN G; LIVER ANTIGEN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ALOPECIA; AUTOIMMUNE HEPATITIS; BILE DUCT; CANCER EPIDEMIOLOGY; CHOLANGIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG DOSE REDUCTION; ETHNIC DIFFERENCE; GRAFT DYSFUNCTION; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER NECROSIS; LIVER TRANSPLANTATION; MATHEMATICAL MODEL; NAUSEA; NONHUMAN; OSTEOPOROSIS; PANCREATITIS; PROGNOSIS; RASH; RELAPSE; REVIEW; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; VOMITING;

BIOLOGICAL MARKERS; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; SEVERITY OF ILLNESS INDEX;

EID: 59649096264     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (215)

1. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97.
2. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-31.
3. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002;6:727-37.
4. Lapierre P, Beland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res 2007;149:107-13.
5. Czaja AJ. Autoimmune hepatitis - Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007;1:113-28.
6. Czaja AJ. Autoimmune hepatitis - Part B: diagnosis. Expert Rev Gastroenterol Hepatol 2007;1:129-43.
7. Montano Loza A, Czaja AJ. Current therapy for autoimmune hepatitis. Nature Clin Pract Gastroenterol Hepatol 2007;4:202-14.
8. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-57.
9. Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S. Ferrara F, Carderi I et al. Type 1 autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006;24:1051-7.
10. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:644-50.
11. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004;39:1631-8.
12. Mohamadnejad M, Malekzadeh R, Nasseri-.Moghaddam S, Hagh-Azali S, Rakhshani N, Tavangar SM el al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005;50:547-51.
13. Johnson PJ, McFarlane IG. Meeting report. International Autoimmune Hepatitis Group. Hepatology 1993:18:998-1005.
14. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
15. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41:207-15.
16. Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 1989;11:303-7.
17. Maggiore G, Porta G, Bernard O, Hadchouel M, Alvarez F, Homberg JC et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990;116:280-2.
18. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997;27:578-82.
19. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2:625-31.
20. Kanda T, Yokosuka O, Hirasawa Y, Imazeki F, Nagao K, Suzuki Y et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology 2005;52:1233-5.
21. Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23:1347-53.
22. Viruet EJ, Torres EA. Steroid treatment in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998;17:297-300.
23. Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13:996-1003.
24. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007;13:953-5.
25. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34:659-65.
26. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004;24:322-9.
27. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997;113:664-8.
28. Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002;97:2670-3.
29. Okano N, Yamamoto K, Sakaguchi K, Miyake Y, Shimada N, Hakoda T et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25:263-70.
30. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am I Surg Pathol 2004;28:471-8.
31. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006;59:246-9.
32. Miyake Y. Iwasaki Y, Terada R. Onishi T, Okamoto R. Takaguchi K el al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 2007:37:801-5.
33. Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol 2007;38:1669-75.
34. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 2005;51;313-33.
35. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-98.
36. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
37. Czaja AJ. Variant forms of autoimmune hepatitis. Curr Gastroenterol Rep 1999;1:63-70.
38. Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001;49:589-94.
39. Washington MK. Autoimmune liver disease: overlap and outliers. Mod Pathol 2007;20 Suppl 1:S15-S30.
40. Premoli A, Morello E, Bo S, Durazzo M. Diagnostic and therapeutic questions in overlap syndromes of autoimmune hepatitis. Minerva Gastroenterol Dietol 2007;53:79-82.
41. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002;6:799-824.
42. Czaja AJ, Amnion HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980;78:518-23.
43. Hegarty JE, Nouri-Aria KT, Portmann B, Eddleston ALWF, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983;3:685-9.
44. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-neg-ative chronic active hepatitis. Gastroenterology 1987;92:215-9.
45. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35:890-7.
46. Montano-Loza A, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27:507-15.
47. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J Clin Gastroenterol 2002;35:75-81.
48. Feld JJ, Dinh H, Arenovich T. Marcus VA, Wanless IR, Heathcote FJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53-62.
49. Schramm C, Kanzler S. Meyer zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001;96:1587-91.
50. Granito A, Muratori L, Pappas G, Muratori P, Ferri S, Cassani F et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005;21:1273-7.
51. Verslype C, George C, Buchel E. Nevens F, Van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005;21:695-9.
52. Al-Chalabi T, Boccato S, Portmann BC. McFarlane 1G. Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral center. J Hepatol 2006;45:575-83.
53. Miyake T, Miyaoka H, Abe M. Furukawa S, Shigematsu S, Furukawa F et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36:139-42.
54. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43:532-8.
55. Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 2008;25:219-39.
56. Czaja AJ. Features and consequences of untreated autoimmune hepatitis. Liver Int. In press 2009.
57. Kanzler S, Gerken G, Lohr H, Galle PR, Meyer zum Buschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001;34:354-5.
58. Montano-Loza A, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007;102:1005-12.
59. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002;6:825-50.
60. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13.
61. Czaja AJ. Emerging treatments for autoimmune hepatitis. Curr Drug Targets Inflamm Allergy 2002;1:317-26.
62. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology 2008;48:169-76.
63. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48:1540-8.
64. Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41:305-14.
65. Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol 2007;53:43-78.
66. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007;46:1828-35.
67. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and responses to therapy. Am J Gastroenterol 2001;96:3390-4.
68. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol 2002;97:2402-7.
69. Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002;50:713-7.
70. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;13:490-5.
71. Czaja AJ, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002;37:302-8.
72. Goldberg AC, Bittencourt PL, Oliveira LC, Ramasawmy R, Marin ML, Palacios SA et al. Autoimmune hepatitis in Brazil: an overview. Scand J Immunol 2007;66:208-16.
73. D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005;25:325-30.
74. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis: biopsy findings and clinical correlations. Am J Surg Path 1995;19:699-708.
75. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988;95:448-53.
76. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-32.
77. Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol 2007;5:898-907.
78. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53.
79. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticostertold-treated autoimmune hepatitis. J Hepatol 1992;14:325-31.
80. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Prevalence of sclerosing cholangitis in autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47:949-57.
81. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem 2005;40:127-64.
82. Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol 2006;2:33-48.
83. Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51:259-64.
84. Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A 1992;89:9739-43.
85. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-64.
86. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:413-9.
87. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002;35:475-83.
88. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984;2:954-6.
89. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996;4l:1733-40.
90. Fusconi M, Cassani F, Zauli D, Lenzi M, Ballardini G, Volta U et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods 1990;130:1-8.
91. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996;24:1068-73.
92. Chretien-Leprince P, Ballot E, Andre C, Olsson NO, Fabien N, Escande A et al. Diagnostic value of anti-F-actin antibodies in a French multicenter study. Ann N Y Acad Sci 2005;1050:266-73.
93. Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006;59:280-4.
94. Guéguen P, Dalekos G, Nousbaum JB, Zachou K, Putterman C, Youinou P et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis. J Clin Immunol 2006;26:495-505.
95. Abuaf N, Johanet C, Chretien P, Martini E, Soulier E, Laperche S et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992;16:892-8.
96. Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004;2:825-30.
97. Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 2003;48:1658-64.
98. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 2004;37:195-201.
99. Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D, Shums Z et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 2006;39:341-8.
100. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30:394-401.
101. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 1990;65:23-30.
102. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993;104:1755-61.
103. Potthoff A, Deterding K, Trautwein C, Flemming P, Strassburg CP, Manns MP et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol 2007;45:15-9.
104. Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence of seronegative autoimmune hepatitis. Dig Dis Sci 2007;52:2433-7.
105. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type 1 autoimmune hepatitis. Gastroenterology 1995;108:1159-66.
106. Kaukinen K, Halme L, Collin P, Färkkilä M, Mäki M, Vehmanen P et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122:881-8.
107. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004;2:107-12.
108. Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci 1992;37:1606-11.
109. Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369-76.
110. Gohlke F, Lohse AW, Dienes HP, Löhr H, Märker-Hermann E, Gerken G et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24:699-705.
111. McNair ANB, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in 5 cases. Am J Gastroenterol 1998;93:777-84.
112. Kim TO, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 2000;95:1130-8.
113. Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100:1516-22.
114. Alvarez F. Autoimmune hepatitis and primary sclerosing cholangitis. Clin Liver Dis 2006;10:89-107.
115. Duclos-Vallee J-C, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: corticore-sistance and effective treatment with cyclosporine A. Dig Dis Sci 1995;40:1069-73.
116. Chazouilleres O, Wendum D, Serfaty L, Montebault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301.
117. Lohse AW, Meyer zum Buschenfelde KH, Kanzler FB, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-84.
118. Renou C, Bourlière M, Martini F, Ouzan D, Penaranda G, Larroque O et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: complete biochemical and histological response to therapy with ursodeoxycholic acid. J Gastroenterol Hepatol 2006;21:781-2.
119. Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44:400-6.
120. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18:10-5.
121. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31:1231-8.
122. Sato Y, Harada K, Sudo Y, Watanabe K, Nakahama T, Morimoto H et al. Autoimmune hepatitis associated with bile duct injury resembling chronic non-suppurative destructive cholangitis. Pathol Int 2002;52:478-82.
123. Heathcote J. Variant syndromes of autoimmune hepatitis. Clin Liver Dis 2002;6:669-84.
124. Czaja AJ. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. J Hepatol 2006;44:251-2.
125. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
126. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984;37:363-5.
127. Devlin J, Donaldson P, Portmann B, Heaton N, Tan KC, Williams R. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl Surg 1995;1:162-5.
128. Ratziu V, Samuel D, Sebagh M, Farges O, Saliba F, Ichai P et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999;30:131-41.
129. Götz G, Neuhaus R, Bechstein WO, Lobeck H, Berg T, Hopf U et al. Recurrence of autoimmune hepatitis after liver transplantation. Transpl Proc 1999;31:430-1.
130. González-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7:302-10.
131. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813-24.
132. Hayashi M, Keeffe EB, Krams SM, Martinez OM, Ojogho ON, So SK et al. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg 1998;4:208-14.
133. Trouillot TE, Shrestha R, Kam I, Wachs M. Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl Surg 1999;5:375-80.
134. Czaja AJ. The immunoreactive propensity of autoimmune hepatitis: is it corticosteroid dependent after liver transplantation? Liver Transpl Surg 1999;5:460-3.
135. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis 2002;22:379-85.
136. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008;14:1281-6.
137. Kerkar N, Hadziç N, Davies ET, Portmann B, Donaldson PT, Rela M et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-13.
138. Jones DEJ, James OFW, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999;30:53-7.
139. Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34:464-70.
140. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology. A rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001;71:664-8.
141. Spada M, Bertani A, Sonzogni A, Petz W, Riva S, Torre G et al. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. Transplant Proc 2001:33:1747-8.
142. Keaveny AP, Gordon FD, Khettry U. Post-liver transplantation de novo hepatitis with overlap features. Pathol Int 2005;55:660-4.
143. Rodríguez-Diaz Y, Reyes-Rodrigtiez R, Dorta-Francisco MC, Aguilera I, Perera-Molinero A, Moneva-Arce E et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant Proc 2006;38:1467-70.
144. Hurtova M, Duclos-Vallée JC, Johanet C, Emile JF, Roque-Afonso AM, Feray C et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl 2001;7:556-8.
145. Salcedo M, Vaquero J, Bañares R, Rodríguez-Mahou M, Alvarez E, Vicario JL et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002:35:349-56.
146. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. QJ Med 1971;40:159-85.
147. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitniçk GL, Elveback IR et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
148. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-7.
149. Koretz RL, Lewin KJ, Higgins J, Fagen ND, Gitnick GL. Chronic active hepatitis. Who meets treatment criteria? Dig Dis Sci 1980;25:695-9.
150. Mistilis SP, Skyring AP, Blackburn CRB. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med 1968;17:214-23.
151. DeGroote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978,19:510-3.
152. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-7.
153. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1-7.
154. Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992;103:1893-901.
155. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805.
156. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end stage liver disease. Hepatology 2007;46:1138-45.
157. Lennard L. The clinical pharmacology of 6-mercap-topurine. Eur J Clin Pharmacol 1992;43:329-39.
158. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mer-captopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33.
159. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51:968-75.
160. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase pheno-type and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002;37:441-7.
161. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-91.
162. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008;7:319-33.
163. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Human Genet 1980;32:651-62.
164. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
165. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001;29:601-5.
166. Gisbert JP, Gonzalez-Guijarro L, Cara C, Pajares JM, Moreno-Otero R. Thiopurine methyltransferase activity in patients with autoimmune hepatitis. Med Clin (Barc) 2003;121:481-4.
167. Gisbert JP, Gomollón F, Cara C, Luna M, González-Lama Y, Pajares JM et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 2007;52:1262-9.
168. Kaskas BA, Louis E, Hindorf U, Schaeffeler E, Deflandre J, Graepler F et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003;52:140-2.
169. Cuffari C. Dassopoulis T, Turnbough L, Thompson RE, BayJess TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-7.
170. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995;85:1897-902.
171. Reuther LO, Sonne J, Larsen NE, Larsen B, Christensen S, Rasmussen SN et al. Pharmacological monitoring of azathioprine therapy. Scand j Gastroenterol 2003;38:972-7.
172. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008;103:1944-51.
173. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
174. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23:116-23.
175. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-7.
176. Johnson PJ, McFarlane IG,. Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-63.
177. Stellon AJ, Keating JJ, Johnson PJ, MacFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988;8:781-4.
178. Banerjee S, Rahhal R, Bishop WP. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2006;43:353-4.
179. Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990;11:1044-9.
180. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001, 48:97-102.
181. Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann Hepatol 2006;5:187-9.
182. Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum 2005;35:49-56.
183. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Preganancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101:556-60.
184. De Boer NK, Jarbandhan SV,. de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006;101:1390-2.
185. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967 97;387-94.
186. Werner M, Björnsson E, Prytz H, Lindgren S, Aimer S, Broomé U et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42:986-91.
187. Whitacre CC, Reingold SC,. O'Looney PA. A gender gap in autoimmunity. Science 1999;283:1277-8.
188. Buchel E, Van Steenbergen W. Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002;97:3160-5.
189. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999;135:111-4.
190. Alvarez F, Ciocca M, Cañero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatof 1999;30:222-7.
191. Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, Gonzalez T, Lopez S et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006;43:635-9.
192. Malekzadeh R, Nasser-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin-A is a promising alternative to corticosteroids- in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-7.
193. Mistilis SP, Vtckers CR, Darroch MH,. McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Australia 1985;143:463-5.
194. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93:890-3.
195. Minuk GY. Cyclosporin A in nontransplant-related liver disease. Am J Gastroenterol 1989;84:1345-50.
196. Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993;17:317-20.
197. Sherman KE,- Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994;21:1040-7.
198. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995;36:459-61.
199. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-8.
200. Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6.
201. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9.
202. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13:3232-6.
203. Pratt DS,. Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996;110:271-4.
204. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
205. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
206. Devlin SM; Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-6.
207. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 200539:819-25.
208. Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN et al Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus, liver Int 2005;25:723-7.
209. Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT et al Mycophenolate mofetil in autoimmune heparins patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007;5:799-802.
210. Hlivto JT. Shiffman ML Stravitz RT Luketic VA. Sanyal AJ, Fuchs M et al A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6:1036-40.
211. Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984;28:485-518.
212. Manns MP, Bahr MJ, Woynarowski M et al. Budesonide 3 mg TID is superior to prednisolone in combination with azathioprine in the treatment of autoimmune hepatitis. J Hepatol 2008;48 Suppl 2:S369.
213. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-6.
214. Wiegand J, Schüler A, Kanzler S, Lohse A, Beuers U, Kreisel W et al Budesonide in previously untreated autoimmune hepatitis, Liver Int 2005;25:927-34.
215. Heneghan MA, Al-Chalabi T, McFarlane IG Cost effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 2006;7:145-56.